Novel Biomarkers and Drug Targets for Cancer Immunotherapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 1574
Special Issue Editors
2. Pittsburgh Trauma and Transfusion Medicine Research Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
Interests: trauma immunology; molecular diagnostics and biomarkers; drug development
Interests: stem cells; premalignancy; disease modeling; drug discovery; nanotechnology; lung cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has revolutionized cancer treatment, providing remarkable advancements in patient outcomes. For this Special Issue, "Novel Biomarkers and Drug Targets for Cancer Immunotherapy", we welcome the submission of papers that explore cutting-edge research in cancer immunology and cell biology, which may be of use for the development of next-generation immunotherapy drugs, cell-based targeting, delivery systems targeting the tumor microenvironment, new biomarkers in cancer theranostics and diagnosis, etc.
This Special Issue delves into the discovery and validation of novel biomarkers with predictive and prognostic significance, elucidating their potential role in guiding precision cancer immunotherapy. Moreover, these articles highlight the identification and characterization of new drug targets, unveiling opportunities for therapeutic interventions that augment immune responses against tumors. Research or reviews are welcome on novel biomarkers, drug targets (such as new molecular targets, synthetic approaches, or optimized drug loading methods) for immunotherapeutic drugs, as well as the original anti-cancer mechanisms based on immunomodulatory and targeting therapy.
The papers featured in this Special Issue will underscore the critical need for personalized cancer immunotherapies, emphasizing the utilization of immune profiling and biomarker-based approaches for patient stratification. We anticipate that these findings will advance the field, opening new frontiers in cancer immunotherapy for the benefit of patients worldwide.
We look forward to receiving your contributions.
Dr. Upendra K. Kar
Dr. Manash Paul
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- novel biomarkers
- drug targets
- precision medicine
- immune profiling
- immunomodulators
- tumor microenvironment
- therapeutic interventions
- nanomedicine-based immunotherapy
- immunotherapeutic drugs
- personalized therapy
- prognostic significance
- predictive markers
